The estimated Net Worth of Violetta Cotreau is at least $63.8 ezer dollars as of 28 February 2022. Ms Cotreau owns over 3,946 units of Akebia Therapeutics stock worth over $41,934 and over the last 4 years she sold AKBA stock worth over $21,841.
Ms has made over 2 trades of the Akebia Therapeutics stock since 2022, according to the Form 4 filled with the SEC. Most recently she sold 3,946 units of AKBA stock worth $8,484 on 28 February 2022.
The largest trade she's ever made was selling 5,833 units of Akebia Therapeutics stock on 3 January 2022 worth over $13,358. On average, Ms trades about 2,445 units every 14 days since 2021. As of 28 February 2022 she still owns at least 29,121 units of Akebia Therapeutics stock.
You can see the complete history of Ms Cotreau stock trades at the bottom of the page.
Violetta Cotreau is the Sr. VP, Chief Accounting Officer & Principal Accounting Officer at Akebia Therapeutics.
Ms Cotreau is 48, she's been the Sr. VP és Chief Accounting Officer & Principal Accounting Officer of Akebia Therapeutics since . There are 12 older and 5 younger executives at Akebia Therapeutics. The oldest executive at Akebia Therapeutics Inc. is Adrian Adams, 69, who is the Independent Chairman of the Board.
Violetta's mailing address filed with the SEC is C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, CAMBRIDGE, MA, 02142.
Over the last 11 years, insiders at Akebia Therapeutics have traded over $3,056,393 worth of Akebia Therapeutics stock and bought 2,141,907 units worth $27,915,834 . The most active insiders traders include Holdings A/S Novo, Muneer A Satter és Mark J Enyedy. On average, Akebia Therapeutics executives and independent directors trade stock every 28 days with the average trade being worth of $43,534. The most recent stock trade was executed by Nicole R. Hadas on 13 May 2024, trading 12,016 units of AKBA stock currently worth $15,140.
akebia therapeutics, inc. is a biopharmaceutical company headquartered in cambridge, massachusetts, focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor (hif) biology. akebia’s lead product candidate, vadadustat, is an investigational oral therapy in development for the treatment of anemia related to chronic kidney disease in both non-dialysis and dialysis patients. akebia’s global phase 3 program for vadadustat, which includes the pro2tect studies for non-dialysis patients with anemia associated with chronic kidney disease and the inno2vate studies for dialysis-dependent patients, is currently ongoing. for more information, please visit our website at www.akebia.com.
Akebia Therapeutics executives and other stock owners filed with the SEC include: